Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197673
Title: | Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors |
Author: | Pérez Lamas, Lucía Luna, Alejandro Boque, Concepción Xicoy, Blanca Giraldo, Pilar Pérez López, Raúl Ruiz Nuño, Concepción Heras, Natalia de las Mora Casterá, Elvira López Marín, Javier Segura Díaz, Adrián Gómez, Valle Vélez Tenza, Patricia Sierra Pacho, Magdalena Vera Goñi, Juan Antonio Moreno Vega, Melania Alvarez Larrán, Alberto Cortés, Montse Pérez Encinas, Manuel Carrascosa Mastell, Patricia Angona, Anna Rosell, Ana Lakhwani, Sunil Colorado, Mercedes Ramila, Elena Cervero, Carlos Cuevas, Beatriz Villalón Blanco, Lucía Paz, Raquel de Paz Coll, Antonio Fernández, María José Felipe Casado, Luis Alonso Domínguez, Juan Manuel Anguita Arance, María Magdalena Salamanca Cuenca, Araceli Jiménez Velasco, Antonio Prendes, Santiago Osorio Santaliestra, Marta Lis Chulvi, María José Hernández Boluda, Juan Carlos García Gutiérrez, Valentín |
Keywords: | Leucèmia mieloide Resistència als medicaments Myeloid leukemia Drug resistance |
Issue Date: | 7-Feb-2023 |
Publisher: | MDPI AG |
Abstract: | Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world setting have been reported, but a detailed analysis of the toxicity profile and the influence of prior intolerance to classical tyrosine kinase inhibitors (TKIs) has not been performed. The aim of the present analysis is to study in detail the toxicity profile of asciminib as well as to describe the risk of cross-toxicity with classical TKIs. These results may help to select the patient profile with the best chance of therapeutic success with asciminib monotherapy. (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers15041045 |
It is part of: | Cancers, 2023, vol. 15, num. 4 |
URI: | http://hdl.handle.net/2445/197673 |
Related resource: | https://doi.org/10.3390/cancers15041045 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-15-01045.pdf | 1.36 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License